0001104659-21-082064.txt : 20210616
0001104659-21-082064.hdr.sgml : 20210616
20210616170607
ACCESSION NUMBER: 0001104659-21-082064
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210614
FILED AS OF DATE: 20210616
DATE AS OF CHANGE: 20210616
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Vogt Frederick G
CENTRAL INDEX KEY: 0001719678
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36860
FILM NUMBER: 211022236
MAIL ADDRESS:
STREET 1: 2120 HEMLOCK RD.
CITY: WEST NORRITON
STATE: PA
ZIP: 19403
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IOVANCE BIOTHERAPEUTICS, INC.
CENTRAL INDEX KEY: 0001425205
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 753254381
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
BUSINESS PHONE: 6502607120
MAIL ADDRESS:
STREET 1: 999 SKYWAY ROAD
STREET 2: SUITE 150
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
FORMER COMPANY:
FORMER CONFORMED NAME: Lion Biotechnologies, Inc.
DATE OF NAME CHANGE: 20131015
FORMER COMPANY:
FORMER CONFORMED NAME: Genesis Biopharma, Inc
DATE OF NAME CHANGE: 20100319
FORMER COMPANY:
FORMER CONFORMED NAME: FREIGHT MANAGEMENT CORP
DATE OF NAME CHANGE: 20080128
4
1
tm2119923-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-06-14
0
0001425205
IOVANCE BIOTHERAPEUTICS, INC.
IOVA
0001719678
Vogt Frederick G
C/O IOVANCE BIOTHERAPEUTICS, INC.
999 SKYWAY ROAD, SUITE 150
SAN CARLOS
CA
94070
0
1
0
0
Interim CEO & General Counsel
Stock Option (right to buy)
23.87
2021-06-14
4
A
0
100000
0
A
2031-06-14
Common Stock
100000
100000
D
Stock Option (right to buy)
23.87
2021-06-14
4
A
0
73900
0
A
2031-06-14
Common Stock
73900
73900
D
Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-third of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant.
Provided the Reporting Person is still employed with the Issuer on the following dates, the options are exercisable as follows: (i) options for the purchase of one-half of such shares shall vest on the one-year anniversary of the date of grant; and (ii) the remaining options shall vest on December 31, 2022.
/s/ Frederick G. Vogt
2021-06-16